Literature DB >> 1510472

[Nephrogenic adenoma of the upper and lower urinary tract. Apropos of 22 cases].

P I Cárcamo Valor1, J P San Millán Arruti, J M Cózar Olmo, M J García-Matres, C Echevarría, L Martínez-Piñeiro, J A Martínez-Piñeiro.   

Abstract

Nephrogenic adenoma (NA) is a lesion that can present in the urothelium--from the renal pelvis to the urethra-, and is considered to be immature metaplasia arising from chronic aggression. We report 22 cases of NA in 21 patients that had been diagnosed and treated in our service from 1975 to 1990. The lesion was found at all levels of the urinary tract: renal pelvis (1 case), ureter (1 case), bladder (16 cases) and urethra (4 cases). The present series was comprised of 15 males (one with bladder NA and recurrence in urethra) and 6 females, with ages ranging from 24 to 79 years (mean 55). The diagnosis was made on the histological findings in all cases and the etiology of the lesion was multiple: previous surgery (11 cases), previous or coexisting urothelial carcinoma (8 cases), intracavitary chemotherapy and/or pelvic radiotherapy (3 cases), previous history of tuberculosis (5 cases), interstitial cystopathy (4 cases), lithiasis (2 cases), permanent catheter (3 cases) and urethral stenosis (1 case). Treatment and prognosis was influenced by the underlying urological disease. NA per se does not carry an unfavourable prognosis.

Entities:  

Mesh:

Year:  1992        PMID: 1510472

Source DB:  PubMed          Journal:  Arch Esp Urol        ISSN: 0004-0614            Impact factor:   0.436


  2 in total

1.  Nephrogenic adenoma of the renal pelvis: A rare case report and review of the literature.

Authors:  Feilong Zhang; Jiyue Wu; Zejia Sun; Dawei Xie; Xiaoyong Yang; Wei Wang
Journal:  Medicine (Baltimore)       Date:  2021-08-27       Impact factor: 1.889

2.  Ureteral Nephrogenic Adenoma in Chronic Recreational Ketamine Abuse.

Authors:  Qingquan Lai; Hainan Zhuang; Huifen Xie
Journal:  Urol Case Rep       Date:  2017-11-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.